Scholar Rock reports Q1 net loss $105.5M; FDA accepts apitegromab BLA with Sep 30 PDUFA

Scholar Rock Holding Corp

2026-Q1 EPS reported -$0.83

FDA accepted apitegromab BLA for SMA; PDUFA action date Sep 30, 2026; two fill-finish facilities included.
Cash of $479.9M as of Mar 31, 2026, includes $100M debt draw and $98M ATM proceeds.
Q1 2026 net loss $105.5M ($0.83 per share) vs $74.7M ($0.67) in Q1 2025; no revenue.
R&D expense $51.8M, G&A $50.2M; stock-based compensation $18.2M.
Pipeline: Phase 2 OPAL trial enrolling; FORGE FSHD trial on track for mid-2026; SRK-439 Phase 1 data H2 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Scholar Rock Holding Corp reported the quarter ended March 31, 2026 results: net income $105.5 million, EPS $0.83.

Period: the quarter ended March 31, 2026
Net income: $105.5 million
EPS: $0.83
Result: reported results

Exact text from the filing

Scholar Rock reported a net loss of $105.5 million, including stock-based compensation of $18.2 million, for the quarter ended March 31, 2026, compared to a net loss of $74.7 million, including stock-based compensation of $13.4 million, for the quarter ended March 31, 2025. Net loss per common share was $0.83 for the quarter ended March 31, 2026, compared to $0.67 per common share for the quarter ended March 31, 2025.

View on SEC.gov

Browse all earnings releases →

Scholar Rock Holding Corp filing history →

Source: SEC EDGAR

accession 0001104659-26-056655

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.